TOKYO, Japan — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that data from Part C of the Phase I/II NXTAGE study, the first clinical data evaluating NXT007 in people switching from emicizumab without a washout period, were presented at the 2026 European Association for Haemophilia and Allied Disorders (EAHAD) Congress held...
Latest News
Duchenne muscular dystrophy is a rare genetic muscle disorder with poor life prognosis, which is difficult to cure and significantly reduces independent living and quality of life due to muscle weakness Approval based on results from clinical studies including a global Phase III clinical study (EMBARK) Approval for ambulatory patients...
Seoul, South Korea – To fill this knowledge gap, a group of researchers led by Professor Kangseok Lee, from the Department of Life Science, Chung-Ang University set out to explore the biogenesis and function of specific tRFs like tRHs. Their study published in Volume 15 of Nature Communications on 28...
SAN DIEGO, Calif. — Cidara Therapeutics Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has approved REZZAYO (rezafungin acetate) for the...
PALO ALTO, Calif. & PHILADELPHIA – Ciitizen, a healthcare technology company that helps patients get full control of their medical records to access better treatment options including participation in research and clinical trials, and the STXBP1 Foundation, a patient advocacy group dedicated to finding a cure for STXBP1 Disorders, today announced...
SOUTH SAN FRANCISCO, Calif. – Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, announced that it has raised $66 million in an oversubscribed Series C financing. The financing was co-led by The Column Group and Nextech Invest. All investors from the prior round...
CRANFORD, N.J. — Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of...
CRANFORD, N.J. — Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator‑initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR‑T therapy in...
SHANGHAI and BOSTON – Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has received a clinical trial waiver from the National Medical Products Administration (NMPA) in China for Wakix® (pitolisant), a narcolepsy drug approved in the European Union and the United States for the treatment of narcolepsy in adult patients with and without...
CAMBRIDGE, Mass. and SHANGHAI – Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. The deal provides Citrine with exclusive rights to develop and commercialize Efmody® (hydrocortisone modified-release hard...